May 2, 2024
Vivifi was honored to be named a TiE50 Award Winner at TiEcon 2024, one of the world’s largest gatherings for founders and investors. TiE Silicon Valley’s TiE50 program spotlights 50 high‑potential startups each year based on innovation, traction and team. Winners pitch in a showcase before investor judges and receive on‑stage recognition at the conference. This year’s ceremony took place on May 2 2024 at the Santa Clara Convention Center during a conference themed “AI Ubiquity: Envision the Future.”
For Vivifi, the award was more than a trophy—it opened doors. TiEcon concentrates operators and capital who turn promising ideas into partnerships and resources. Being on the TiE50 slate put our function‑preserving approach to benign prostatic hyperplasia (BPH) in front of the people who can compress timelines for evidence generation and market entry. This recognition underscores the relevance of our mission to make BPH care simpler and more humane.
TiEcon is the flagship conference of TiE (The Indus Entrepreneurs) Silicon Valley. It brings together entrepreneurs, investors and corporate leaders from around the world for keynotes, workshops and networking. The TiE50 awards program, now in its seventeenth year, highlights early‑ to mid‑stage technology companies that demonstrate innovation and traction. Selected startups pitch to investor judges, and winners are recognized during the conference. Over the years the program has provided exposure to companies that have collectively raised more than a billion dollars in funding.
Vivifi Medical is a Houston‑based medical device company developing a minimally invasive, function‑preserving treatment for benign prostatic hyperplasia. Our team combines urology, vascular and device‑design expertise to create solutions that respect anatomy and quality of life. We are committed to partnering with clinicians and investors who share our vision of better outcomes and faster recovery for men with BPH.
2450 Holcombe Blvd, Ste 1420, Houston, TX 77021* NOTE: This treatment is for investigational use only and is not approved by the FDA for commercial distribution. It is currently under clinical investigation to evaluate its safety and effectiveness.
